Here, Dr Natasha Varvogli, intellectual property consultant, and Maria Andrielou, marketing & communication at VIO Chemicals, look at patents and their role in the pharma industry.
Michael Avraam, global product manager at ChargePoint Technology discusses the evolution of containment strategies, specifically within the role of containment verification and monitoring technology.
Machine learning offers considerable potential for streamlining and transforming routine information processes in life sciences — but could more creative applications of artificial intelligence take things further still? AMPLEXOR’s Siniša Belina asse
Dr Andrew Rut, CEO of SaaS provider My Meds & Me discusses why AI can revolutionise drug development and healthcare but caution over data is critical for success.
GlobalData, a data and analytics company, has reported that further development of chimeric antigen receptor (CAR)-T cell therapies in solid tumours will require collaboration with industry.
In this exclusive interview, we discuss the digitalisation of the supply chain, compliance with European Falsified Medicines Directive and TraceLink’s Product Information Manager with the company’s vice president, solutions marketing, Dan Walles.
Data and analytics company, GlobalData, has revealed that it believes new launches into the epinephrine injection device market will have the potential to completely transform the space.
In preparations for Brexit, the EMA has redistributed the UK’s product portfolio to other EU members and is not allocating any centralised marketing authorisation applications to the MHRA. We take a closer look…
Colin Newbould, the Wasdell Group, discusses upcoming deadlines and what companies should be thinking about as the scope and requirements of track and trace legislation continue to change.
As the deadlines for the US Drug Supply Chain Security Act (DSCSA) and the Falsified Medicines Directive (FMD) near, pharma businesses should be prioritising the validation of their solutions. Here, Lauren Catalano, Sharp Services, offers guidance
Rapid growth from $1.64 billion in 2017 to $6.07 billion in 2024 is expected in the global orphan and rare dermatology premium products market, according to business intelligence provider, GBI Research.
